$0.19 EPS Expected for Lantheus Holdings, Inc. (LNTH)

September 30, 2018 - By Carolyn Hewitt

Analysts expect Lantheus Holdings, Inc. (NASDAQ:LNTH) to report $0.19 EPS on November, 1.They anticipate $0.05 EPS change or 20.83 % from last quarter’s $0.24 EPS. LNTH’s profit would be $7.28M giving it 19.67 P/E if the $0.19 EPS is correct. After having $0.26 EPS previously, Lantheus Holdings, Inc.’s analysts see -26.92 % EPS growth. The stock increased 2.75% or $0.4 during the last trading session, reaching $14.95. About 249,073 shares traded. Lantheus Holdings, Inc. (NASDAQ:LNTH) has declined 8.62% since September 30, 2017 and is downtrending. It has underperformed by 24.24% the S&P500.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide. The company has market cap of $572.58 million. The Company’s principal products include DEFINITY, an ultrasound contrast imaging agent for use in patients with suboptimal echocardiograms; TechneLite, a self-contained system or generator of technetium used by radiopharmacies to prepare various nuclear imaging agents; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging of cerebral blood flow. It has a 4.76 P/E ratio. The firm also offers injectable technetium-labeled imaging agents, including Cardiolite, used in myocardial perfusion imaging procedures; and Neurolite, which is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke.

Another recent and important Lantheus Holdings, Inc. (NASDAQ:LNTH) news was published by Uk.Finance.Yahoo.com which published an article titled: “What You Must Know About Lantheus Holdings Inc’s (NASDAQ:LNTH) Market Risks” on September 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: